A One-Year, Prospective, Randomized, Controlled Study Evaluating The Efficacy Of Switching From The Twice Daily Tacrolimus Formulation To The Extended Release, Once Daily Formulation To Reduce The Framingham Cardiovascular Risk Scores.
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 11 Jan 2017
At a glance
- Drugs Tacrolimus (Primary)
- Indications Renal transplant rejection
- Focus Biomarker; Pharmacodynamics
- Acronyms ESTTEROD
- 05 Jan 2017 Planned End Date changed from 1 Jun 2016 to 1 Jul 2017.
- 05 Jan 2017 Planned primary completion date changed from 1 Jun 2016 to 1 Jul 2017.
- 02 Jun 2015 Planned End Date changed from 1 Apr 2014 to 1 Jun 2016 as reported by ClinicalTrials.gov.